Why the study?
How should upper gastrointestinal haemorrhage complicating dual anti-platelet therapy be managed?
How should upper gastrointestinal haemorrhage complicating dual anti-platelet therapy be managed?
This review highlights the clinical challenge of managing upper GI bleeding in patients on dual antiplatelet therapy, emphasizing individualized therapy adjustments and endoscopic intervention.
Answers are grounded in this paper and cite their sources.
Individualized DAPT management in upper GI bleed warrants caution; review extends synthesis but leaves optimal protocols open for trials.
Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality. Using an illustrative case this article examines the prognostic significance of gastrointestinal haemorrhage and the risk of stopping anti-platelet therapy. The management of this clinical challenge is reviewed, in the absence of a clinical guideline, with particular reference to the judicious tailoring of anti-platelet therapy, the role of therapeutic endoscopy and the utility of blood transfusion.
No takes yet. Share an insight, caveat, or question.
Henriksen et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: